FDA Panel’s Vote Over Weight-Loss Drug Xenical Results in Tie
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Panel’s Vote Over Weight-Loss Drug Xenical Results in Tie

BASEL, SWITZERLAND -- March 16, 1998 -- The United States Food and Drug Administration’s endocrinologic and metabolic drugs advisory committee is deadlocked at five to five on recommending approval of F. Hoffmann-La Roche Ltd.’s weight management drug Xenical(R) (orlistat).

Roche said it would meet shortly with the FDA staff to discuss the recommendation. Roche reaffirms its belief that orlistat has an important role to play in the management of obesity and looks forward to discussing next steps with the FDA.

In May 1997 the panel unanimously recommended the approval of Xenical, a lipase inhibitor which acts in the gastrointestinal tract to decrease fat absorption by about 30 percent. Drugs in this class do not achieve their effect through brain chemistry.

Previous studies showed that Xenical-treated patients had statistically significant reductions in total and LDL cholesterol and systolic and diastolic blood pressure, as well as improvements in blood concentrations of glucose and insulin after one year over placebo with diet.

More information on: Hoffmann-La Roche and, More information on: Xenical

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities